The brain tries to repair damage after a stroke by utilizing its own repair cells, which function like skilled craftsmen.

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

INSIHGT is an affordable, non-destructive and accessible 3D spatial biology method that maps diverse biomolecules deep within tissues, such as proteins and RNA, thus advancing the understanding of ...

A team led by UT Southwestern scientists has discovered a mechanism that promotes metastasis in pancreatic, breast, and ...

The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and ...

A new study sheds light on one of the most severe consequences of stroke: damage to the brain's 'cables'-- the so-called nerve fibers -- which leads to permanent impairments.

A new state-of-the-art immunohistochemistry (IHC) machine, installed at the National Public Health Laboratory in Kingston, ...

A new study by researchers at the Department of Molecular Medicine at SDU sheds light on one of the most severe consequences ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.